Clover Biopharmaceuticals Ltd. (2197)
HKEX HKEX Primary Summary
Clover Biopharmaceuticals Ltd. (2197) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Clover Biopharmaceuticals Ltd. ever had a stock split?
Clover Biopharmaceuticals Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Joshua G. Liang CEO | HKEX Exchange | KYG2280A1076 ISIN |
| China Country | 243 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Clover Biopharmaceuticals, Ltd. is a pioneering biotechnology entity dedicated to the discovery, development, and commercialization of innovative vaccine and biologic therapies. Operating since 2007 with its headquarters based in Shanghai, China, the company positions itself at the forefront of responding to the pressing global medical challenges. Leveraging cutting-edge technology and scientific excellence, Clover Biopharmaceuticals is committed to creating a healthier future through its contributions to vaccine and therapeutic developments.
Products and Services
Clover Biopharmaceuticals' unique portfolio spans across vaccines and therapeutic candidates aimed at addressing unmet medical needs worldwide. Each product underscores the company’s innovative approach and technical prowess, employing the proprietary Trimer-Tag technology platform for development. The key offerings include:
- SCB-2019 (CpG 1018/Alum): An adjuvanted protein-based COVID-19 vaccine candidate, highlighting the company's swift response to the global pandemic with a focus on safety and efficacy.
- AdimFlu-S (QIS): A quadrivalent vaccine targeting the influenza virus, showcasing the company’s commitment to broadening its vaccine portfolio beyond the COVID-19 pandemic.
- SCB-2020S (CAS-1) and Multivalent SARS-CoV-2: Additional COVID-19 vaccine candidates, demonstrating Clover Biopharmaceuticals’ relentless pursuit of pandemic preparedness and health security.
- SCB-313: A trimeric fusion protein aimed at the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis. This product targets the unmet medical need in intracavitary malignancies, emphasizing the company’s focus on cancer therapy.
- SCB-219M: A human thrombopoietin receptor agonist (TPO-RA) currently in Phase 1 trial, developed for the treatment of chemotherapy-induced thrombocytopenia. This showcases the company's commitment to addressing complications associated with cancer treatments.
- SCB-1001: A rabies vaccine candidate, further diversifying the company's extensive portfolio and addressing the critical need for effective rabies prevention.
